ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0550

Harnessing Machine Learning to Predict Neuropsychiatric Events in Systemic Lupus Erythematosus

Nursen Cetrez1, Julius Lindblom1, Raffaele Da Mutten2, Dionysis Nikolopoulos2 and Ioannis Parodis1, 1Karolinska Institutet, Stockholm, Sweden, 2Karolinska Institutet and Karolinska University Hospital, Division of Rheumatology, Department of Medicine Solna, Stockholm, Sweden

Meeting: ACR Convergence 2023

Keywords: autoimmune diseases, B-Cell Targets, Biostatistics, neuropsychiatric disorders, Systemic lupus erythematosus (SLE)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, November 12, 2023

Title: (0543–0581) SLE – Diagnosis, Manifestations, & Outcomes Poster I

Session Type: Poster Session A

Session Time: 9:00AM-11:00AM

Background/Purpose: Neuropsychiatric systemic lupus erythematosus (NPSLE) is linked to increased morbidity, mortality, and adverse health-related quality of life. Early disease, a history of NPSLE, aPL positivity, and high disease activity are considered risk factors for NPSLE. However, there is currently no reliable clinical tool to predict neuropsychiatric flares. Recent advancements in machine learning (ML) have demonstrated great potential in aiding clinical decision-making across various medical disciplines. Therefore, we aimed to assess the reliability and effectiveness of ML applications in predicting NPSLE flares within a large cohort of patients with active SLE, yet no ongoing active severe NPSLE.

Methods: We analysed data from five phase III trials (BLISS-52, BLISS-76, BLISS-NEA, BLISS-SC, EMBRACE) after exclusion of patients with baseline neuropsychiatric BILAG score A (N=3638). Neuropsychiatric flares were defined as a transition from BILAG score C, D, or E to score A or B, or from score B to score A in the neuropsychiatric domain of the classic BILAG index throughout a 52-week long follow-up. After constructing panels of variables based on expert knowledge, we employed ML methodology to develop predictive models utilising the least absolute shrinkage and selection operator (LASSO) as well as multivariable logistic regression analysis. A stratified split was applied to the data to partition the study population into a training (70%; N=2547), and a test set (30%; N=1091). The training set was used in model development while the internal validation was developed by a 10 times 10-fold cross validation. The test set was used for validation of the built model, and the performance of the two models was demonstrated using area under the curve (AUC) of the receiver operating curves (ROC), accuracy with a 95% confidence interval (CI), sensitivity, and specificity metrics.

Results: A total of 105 SLE patients (2.89%) experienced a neuropsychiatric flare during follow-up. Knowledge-driven feature selection included a history of NPSLE, disease duration, aCL positivity, clinical SLEDAI-2K, sex, age, and the use of antimalarials. The LASSO and multivariable logistic regression models demonstrated comparable performance, with an AUC of 0.80 and 0.80, sensitivity of 0.61 and 0.61, and specificity of 0.83 and 0.82, respectively. Moreover, both algorithms exhibited appropriate calibration on the test dataset.

Conclusion: The integration of traditional risk factors for NPSLE into ML-based models can predict neuropsychiatric involvement in SLE with high specificity and modest sensitivity. We herein propose a pragmatic, robust, and highly accurate prediction tool forecasting neuropsychiatric flares in patients with SLE. The utilisation of this ML-based tool holds promising prospects for improving patient care and outcomes in real-world settings.


Disclosures: N. Cetrez: None; J. Lindblom: None; R. Da Mutten: None; D. Nikolopoulos: None; I. Parodis: Amgen, 5, 6, AstraZeneca, 5, 6, Aurinia Pharmaceuticals, 5, 6, Bristol-Myers Squibb(BMS), 5, 6, Elli Lilly and Company, 5, 6, F. Hoffmann-La Roche AG, 5, 6, Gilead Sciences, 5, 6, GSK, 5, 6, Janssen Pharmaceuticals, 5, 6, Novartis, 5, 6, Otsuka Pharmaceutical, 5, 6.

To cite this abstract in AMA style:

Cetrez N, Lindblom J, Da Mutten R, Nikolopoulos D, Parodis I. Harnessing Machine Learning to Predict Neuropsychiatric Events in Systemic Lupus Erythematosus [abstract]. Arthritis Rheumatol. 2023; 75 (suppl 9). https://acrabstracts.org/abstract/harnessing-machine-learning-to-predict-neuropsychiatric-events-in-systemic-lupus-erythematosus/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2023

ACR Meeting Abstracts - https://acrabstracts.org/abstract/harnessing-machine-learning-to-predict-neuropsychiatric-events-in-systemic-lupus-erythematosus/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology